IL-18 ELISA Kit

Catalog No. ABIN4986936

Product Details IL-18 ELISA Kit

Target: IL-18 (IL18) (Interleukin 18 (IL18))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 78-5000 pg/mL

Minimum Detection Limit: 78 pg/mL

Application: ELISA

Sample Type: Cell Culture Supernatant, Serum, Plasma (heparin), Plasma (citrate), Plasma (EDTA)

Analytical Method: Quantitative

Specificity: Natural and recombinant Human IL-18 Ligand

Sensitivity: 20 pg/mL

Material not included:

• Microplate reader.
• Pipettes and pipette tips.
• EP tube Deionized or distilled water.

Application Details

Application Notes: Detection Wavelength: 450 nm

Sample Volume: 20 μL

Assay Time: 3 h

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Storage: 4 °C

Target Details for IL-18

Target: IL-18 (IL18) (Interleukin 18 (IL18))

Alternative Name: IL-18 (IL18 Products)

Synonyms: Igif ELISA Kit, Il-18 ELISA Kit, IL-18 ELISA Kit, IGIF ELISA Kit, ChIL-18 ELISA Kit, IL-1g ELISA Kit, IL1F4 ELISA Kit, IL18 ELISA Kit, interleukin 18 ELISA Kit, Il18 ELISA Kit, IL18 ELISA Kit

Background: Interleukin (IL) -18 is a newly discovered cytokine, structurally similar to IL-1, with profound effects on T-cell activation. Formerly called interferon (IFN) gamma inducing factor (IGIF), IL-18 is a novel cytokine that plays an important role in the T-cell-helper type 1 (Th1) response, primarily by its ability to induce IFN gamma production in T cells and natural killer (NK) cells. In terms of structure, IL-18 and IL-1 beta share primary amino acid sequences of the so-called "signature sequence" motif and are similarly folded as all beta pleated sheet molecules. Also similar to IL-1 beta, IL-18 is synthesized as a biologically inactive precursor molecule lacking a signal peptide which requires cleavage into an active, mature molecule by the intracellular cysteine protease called IL-1 beta-converting enzyme (ICE, caspase-1). Therefore inhibitors of ICE activity may limit the biologic activity of IL-18 and may be useful as Th1 immunosuppressive agents. The activity of the mature IL-18 is closely related to that of IL-1. IL-18 induces gene expression and synthesis of tumor necrosis factor (TNF), IL-1, Fas Ligand, and several chemokines. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. The activity of IL-18 is via an IL-18 receptor (IL-18R) complex. This complex is made up of a binding chain termed IL-18R?, a member of the IL-1 receptor family previously identified as the IL-1 receptor - related protein (IL-1Rrp), and a signaling chain, also a member of the IL-1R family. The IL-18R complex recruits the IL-1R - activating kinase (IRAK) and TNF-R - associated factor -6 (TRAF-6) with subsequent activation of NF kappa B. Thus based on primary structure, three-dimensional structure, receptor family, signal transduction pathways and biological effects, IL-18 appears to be a new member of the IL-1 family. Similar to IL-1, IL-18 participates in both innate and acquired immunity. Constitutive IL-18 expression is detected from many different cells, including macrophages, keratinocytes, and osteoblasts. Human keratinocytes have been found to be the major producers of IL-18 in unprocessed form. An important role of IL-18 has been shown in clinical implications, in the role of IL-18 modulation in tumours, infections, and autoimmune and inflammatory diseases. Elevated serum levels of IL-18 have been shown in patients with acute graft-versus-host disease after bone marrow transplantation. Highly elevated IL-18 bioactivity with highly elevated serum IL-18 levels are measured in hematological malignancies as well as in sepsis. Increased concentrations of plasma IL-18 are found in patients with hepatic dysfunction after hepatectomy and in inflammatory liver diseases. Elevations of IL-18 levels accompany autoimmune disorders like systemic lupus erythematosus and rheumatoid arthritis. Significant levels of circulating IL-18 are found in HIV-1 infection, and other infections, in inflammatory CNS diseases, in Crohn?s disease and in pregnancy during labour and complicated pregnancies. IL-18 is regarded as a novel player in tumour immunotherapy.

Pathways: Cellular Response to Molecule of Bacterial Origin, Activated T Cell Proliferation, Cancer Immune Checkpoints, Inflammasome